JCR Pharmaceuticals Co., Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2024. For the full year, the company expected net sales of JPY 45,400 million, operating income of JPY 10,500 million, profit attributable to owners of parent of JPY 7,300 million and basic earnings per share of JPY 58.71 against previous forecast of net sales of JPY 36,900 million, operating profit of JPY 5,600 million, profit attributable to owners of parent of JPY 3,800 million and basic earnings per share of JPY 30.56.